Carlos Cordon-Cardo

Tumor response to radiotherapy regulated by endothelial cell apoptosis.

Lack of p53 nuclear immunostaining is not indicative of absence of TP53 gene mutations in colorectal adenocarcinomas.

Array-based comparative genomic hybridization for genome-wide screening of DNA copy number in bladder tumors.

Oncogenes in melanoma.

A multigenic program mediating breast cancer metastasis to bone.

Altered expression of p27 and Skp2 proteins in prostate cancer of African-American patients.

Gene discovery in bladder cancer progression using cDNA microarrays.

Classification and subtype prediction of adult soft tissue sarcoma by functional genomics.

Tumor suppressor role for myopodin in bladder cancer: loss of nuclear expression of myopodin is cell-cycle dependent and predicts clinical outcome.

Adrenocortical adenoma and carcinoma: histopathological and molecular comparative analysis.

Pharmacologic inactivation of kinase suppressor of ras-1 abrogates Ras-mediated pancreatic cancer.

Tumor promotion by Mdm2 splice variants unable to bind p53.

p73alpha regulation by Chk1 in response to DNA damage.

Mutations of the PML tumor suppressor gene in acute promyelocytic leukemia.

Genetic signatures of differentiation induced by 1alpha,25-dihydroxyvitamin D3 in human colon cancer cells.

Comparison of gene expression profiles in laser-microdissected, nonembedded, and OCT-embedded tumor samples by oligonucleotide microarray analysis.

p73 Expression in human normal and tumor tissues: loss of p73alpha expression is associated with tumor progression in bladder cancer.

Pten dose dictates cancer progression in the prostate.

MDM2 and prognosis.

Loss of the tumor suppressor PML in human cancers of multiple histologic origins.

Histone deacetylase inhibitors: assays to assess effectiveness in vitro and in vivo.

p53 and RB: simple interesting correlates or tumor markers of critical predictive nature?

Application of new in situ hybridization probes for Ku70 and Ku80 in tissue microarrays of paraffin-embedded malignant melanomas: correlation with immunohistochemical analysis.

Decreased retinoid X receptor-alpha protein expression in basal cells occurs in the early stage of human prostate cancer development.

Inhibition of orthotopic human bladder tumor growth by lentiviral gene transfer of endostatin.

Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy.

The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis.

Altered expression and new mutations in DNA mismatch repair genes MLH1 and MSH2 in melanoma brain metastases.

High-resolution characterization of the pancreatic adenocarcinoma genome.

Hyperphosphorylation of pRb: a mechanism for RB tumour suppressor pathway inactivation in bladder cancer.

Analysis of adenomatous polyposis coli gene expression, APC locus-microsatellite instability and APC promoter methylation in the progression of melanocytic tumours.

Comparison of DNA ploidy status and DNA ploidy-related parameters in malignant melanoma tissue microarrays and full sections.

Caenorhabditis elegans ABL-1 antagonizes p53-mediated germline apoptosis after ionizing irradiation.

Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer.

Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control.

Cytokeratin positivity in paraffin-embedded malignant melanomas: comparative study of KL1, A4 and Lu5 antibodies.

Genetic and immunophenotype analyses of TP53 in bladder cancer: TP53 alterations are associated with tumor progression.

Glutathione S-transferase P1 Ile105Val polymorphism, cigarette smoking and prostate cancer.

Racial disparity of epidermal growth factor receptor expression in prostate cancer.

Role of Dok-1 and Dok-2 in leukemia suppression.

Application of in situ hybridization probes for MLH-1 and MSH-2 in tissue microarrays of paraffin-embedded malignant melanomas: correlation with immunohistochemistry and tumor stage.

Molecular profiling of tumor progression in head and neck cancer.

Role of the proto-oncogene Pokemon in cellular transformation and ARF repression.

Safety and biologic activity of intravenous BCL-2 antisense oligonucleotide (G3139) and taxane chemotherapy in patients with advanced cancer.

Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism.

p73beta-Mediated apoptosis requires p57kip2 induction and IEX-1 inhibition.

Drg1 expression in 131 colorectal liver metastases: correlation with clinical variables and patient outcomes.

A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol.

A microRNA polycistron as a potential human oncogene.

Genetic analysis of Pten and Tsc2 functional interactions in the mouse reveals asymmetrical haploinsufficiency in tumor suppression.

Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis.

Cytokeratin expression correlates with aneuploidy in cytological specimens of melanoma metastases.

Expression of p63 in diffuse large B-cell lymphoma.

Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants.

Gene expression profiling in single cells within tissue.

A novel multiplexing, polymerase chain reaction-based assay for the analysis of chromosome 18q status in colorectal cancer.

Tobacco smoking, GSTP1 polymorphism, and bladder carcinoma.

Relationship of nm23 expression to proliferation and prognosis in malignant melanomas of the oral cavity.

Proposal of a new grading system for malignant fibrous histiocytomas.

A novel logistic model based on clinicopathological features predicts microsatellite instability in colorectal carcinomas.

[Molecular protocol for HER2/neu analysis in breast carcinoma].

Differential exoprotease activities confer tumor-specific serum peptidome patterns.

Profiling bladder cancer using targeted antibody arrays.

Amplification of CDK4 and MDM2 in malignant melanoma.

Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays.

Loss of Ku70/Ku80 expression occurs more frequently in hereditary than in sporadic colorectal tumors. Tissue microarray study.

Identification of a tumour suppressor network opposing nuclear Akt function.

Autocrine PDGFR signaling promotes mammary cancer metastasis.

Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach.

Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene.

Altered expression of DNA double-strand repair genes Ku70 and Ku80 in carcinomas of the oral cavity.

Analysis of DNA mismatch repair gene expression and mutations in thyroid tumours.

Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo.

PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR.

Evaluation of Ki67, p53 and angiogenesis in patients enrolled in a randomized study of neoadjuvant chemotherapy with or without cystectomy: a Southwest Oncology Group Study.

Alterations of the retinoblastoma and p16 pathway correlate with promoter methylation in malignant fibrous histiocytomas.

Mad2 overexpression promotes aneuploidy and tumorigenesis in mice.

Technology insight: will systems pathology replace the pathologist?

NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN.

Ubiquitination regulates PTEN nuclear import and tumor suppression.

Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas.

Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis.

Relation between human papillomavirus positivity and p16 expression in head and neck carcinomas--a tissue microarray study.

Role of the chromobox protein CBX7 in lymphomagenesis.

Molecular alterations associated with bladder cancer progression.

The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas.

A polymorphism in HDM2 (SNP309) associates with early onset in superficial tumors, TP53 mutations, and poor outcome in invasive bladder cancer.

Prognostic significance of p27Kip1 expression in bladder cancer.

Improved prediction of prostate cancer recurrence through systems pathology.

Tissue-specific and reversible RNA interference in transgenic mice.

Highly efficient gene delivery for bladder cancers by intravesically administered replication-competent retroviral vectors.

Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer.

Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia.

Declining p53 function in the aging process: a possible mechanism for the increased tumor incidence in older populations.

Somatic cell type specific gene transfer reveals a tumor-promoting function for p21(Waf1/Cip1).

Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway.

Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progression.

Genomic and proteomic profiles reveal the association of gelsolin to TP53 status and bladder cancer progression.

Bax and Bak do not exhibit functional redundancy in mediating radiation-induced endothelial apoptosis in the intestinal mucosa.

A context dependent role for Wnt signaling in tumorigenesis and stem cells.

TREK-1 is a novel molecular target in prostate cancer.

A developmental model of sarcomagenesis defines a differentiation-based classification for liposarcomas.

Gli activity correlates with tumor grade in platelet-derived growth factor-induced gliomas.

DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma.

Chk2 suppresses the oncogenic potential of DNA replication-associated DNA damage.

Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events.

Systems pathology approach for the prediction of prostate cancer progression after radical prostatectomy.

Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model.

Molecular alterations associated with bladder cancer initiation and progression.

Associations between variants of the 8q24 chromosome and nine smoking-related cancer sites.

Alveolar rhabdomyosarcoma: is the cell of origin a mesenchymal stem cell?

Comparison of models to predict clinical failure after radical prostatectomy.

p53 is localized to a sub-nucleolar compartment after proteasomal inhibition in an energy-dependent manner.

Identification of PMF1 methylation in association with bladder cancer progression.

Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia.

Differential requirement of mTOR in postmitotic tissues and tumorigenesis.

ETS rearrangements and prostate cancer initiation.

Correlation of MR imaging and MR spectroscopic imaging findings with Ki-67, phospho-Akt, and androgen receptor expression in prostate cancer.

Inactivation of p53 and Pten promotes invasive bladder cancer.

A systems pathology model for predicting overall survival in patients with refractory, advanced non-small-cell lung cancer treated with gefitinib.

Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate.

Prediction of prostate cancer recurrence using magnetic resonance imaging and molecular profiles.

Personalized prediction of tumor response and cancer progression on prostate needle biopsy.

Cyfip1 is a putative invasion suppressor in epithelial cancers.

Systems pathology: a paradigm shift in the practice of diagnostic and predictive pathology.

3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma.

Androgen receptor expression is associated with prostate cancer-specific survival in castrate patients with metastatic disease.

MFH classification: differentiating undifferentiated pleomorphic sarcoma in the 21st Century.

The N-Myc-DLL3 cascade is suppressed by the ubiquitin ligase Huwe1 to inhibit proliferation and promote neurogenesis in the developing brain.

Intravesical delivery of rapamycin suppresses tumorigenesis in a mouse model of progressive bladder cancer.

Overexpression of phospho-eIF4E is associated with survival through AKT pathway in non-small cell lung cancer.

miR-19 is a key oncogenic component of mir-17-92.

Single nucleotide polymorphisms of 8 inflammation-related genes and their associations with smoking-related cancers.

PHF6 mutations in T-cell acute lymphoblastic leukemia.

Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence.

Galectin-3 expression is associated with bladder cancer progression and clinical outcome.

Associations between NBS1 polymorphisms, haplotypes and smoking-related cancers.

Integrative genome comparison of primary and metastatic melanomas.

Molecular pathways of urothelial development and bladder tumorigenesis.

Impact of stromal sensitivity on radiation response of tumors implanted in SCID hosts revisited.

Association of nuclear localization of a long interspersed nuclear element-1 protein in breast tumors with poor prognostic outcomes.

The TLX1 oncogene drives aneuploidy in T cell transformation.

Disruption of a Sirt1-dependent autophagy checkpoint in the prostate results in prostatic intraepithelial neoplasia lesion formation.

Hydrophilic agarose macrobead cultures select for outgrowth of carcinoma cell populations that can restrict tumor growth.

Three-dimensional culture of mouse renal carcinoma cells in agarose macrobeads selects for a subpopulation of cells with cancer stem cell or cancer progenitor properties.

CpG ODN, Toll like receptor (TLR)-9 agonist, inhibits metastatic colon adenocarcinoma in a murine hepatic tumor model.

Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression.

Alternate PAX3 and PAX7 C-terminal isoforms in myogenic differentiation and sarcomagenesis.

KISS1 methylation and expression as tumor stratification biomarkers and clinical outcome prognosticators for bladder cancer patients.

A comparison of the outcomes of neoadjuvant and adjuvant chemotherapy for clinical T2-T4aN0-N2M0 bladder cancer.

A systems-based modelling approach using transurethral resection of the prostate (TURP) specimens yielded incremental prognostic significance to Gleason when predicting long-term outcome in men with localized prostate cancer.

Postoperative systems models more accurately predict risk of significant disease progression than standard risk groups and a 10-year postoperative nomogram: potential impact on the receipt of adjuvant therapy after surgery.

A Role for PML in Innate Immunity.

Predictive value of microtubule associated proteins tau and stathmin in patients with nonmuscle invasive bladder cancer receiving adjuvant intravesical taxane therapy.

Anatomical features of the urethra and urinary bladder catheterization in female mice and rats. An essential translational tool.

Personalized approach to prostate cancer prognosis.

PPARγ agonists enhance ET-743-induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcoma.

Mouse models of human bladder cancer as a tool for drug discovery.

PAX7-FKHR fusion gene inhibits myogenic differentiation via NF-kappaB upregulation.

miR-143, miR-222, and miR-452 are useful as tumor stratification and noninvasive diagnostic biomarkers for bladder cancer.

Perioperative polyphenon E, a green tea extract, does not affect the wound complication rate in mice after sham laparotomy yet has an inhibitory effect on wound healing.

Translocation renal cell carcinomas in adults: a single-institution experience.

A BAC-based transgenic mouse specifically expresses an inducible Cre in the urothelium.

Preclinical analysis of the γ-secretase inhibitor PF-03084014 in combination with glucocorticoids in T-cell acute lymphoblastic leukemia.

Targeting nonclassical oncogenes for therapy in T-ALL.

Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells.

MAGE-A3 is highly expressed in a subset of colorectal cancer patients.

A common MicroRNA signature consisting of miR-133a, miR-139-3p, and miR-142-3p clusters bladder carcinoma in situ with normal umbrella cells.

Predicting high-risk disease using tissue biomarkers.

Compound In Vivo Inactivation of Pml and p53 Uncovers a Functional Interaction in Angiosarcoma Suppression.

Loss of PML cooperates with mutant p53 to drive more aggressive cancers in a gender-dependent manner.

Dual Pten/Tp53 suppression promotes sarcoma progression by activating Notch signaling.

A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer.

Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion.

Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia.

RapidCaP, a Novel GEM Model for Metastatic Prostate Cancer Analysis and Therapy, Reveals Myc as a Driver of Pten-Mutant Metastasis.

Genomic analysis in active surveillance: predicting high-risk disease using tissue biomarkers.

The miR-424(322)/503 cluster orchestrates remodeling of the epithelium in the involuting mammary gland.

Defining the role of CD2 in disease progression and overall survival among patients with completely resected stage-II to -III cutaneous melanoma.

FBXW7 mutations in melanoma and a new therapeutic paradigm.

Characterization of desmoglein expression in the normal prostatic gland. Desmoglein 2 is an independent prognostic factor for aggressive prostate cancer.

A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia.

Bladder cancers arise from distinct urothelial sub-populations.

The microRNA 424/503 cluster reduces CDC25A expression during cell cycle arrest imposed by transforming growth factor β in mammary epithelial cells.

Overcoming tumor heterogeneity in the molecular diagnosis of urological cancers.

Biomarkers for bladder cancer management: present and future.

ΔNp63 expression is a protective factor of progression in clinical high grade T1 bladder cancer.

Loss of Sirt1 promotes prostatic intraepithelial neoplasia, reduces mitophagy, and delays PARK2 translocation to mitochondria.

Limited miR-17-92 overexpression drives hematologic malignancies.

Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma.

A genetic platform to model sarcomagenesis from primary adult mesenchymal stem cells.

Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis.

A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer.

Methodological aspects of the molecular and histological study of prostate cancer: focus on PTEN.

MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2.

PI3K/AKT pathway regulates E-cadherin and Desmoglein 2 in aggressive prostate cancer.

Inhibition of the autocrine IL-6-JAK2-STAT3-calprotectin axis as targeted therapy for HR-/HER2+ breast cancers.

Expression of the cancer testis antigen IGF2BP3 in colorectal cancers; IGF2BP3 holds promise as a specific immunotherapy target.

Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in T cell acute lymphoblastic leukemia.

H-RAS mutation is a key molecular feature of pediatric urothelial bladder cancer. A detailed report of three cases.

Immunopathologic Assessment of PTEN Expression.

Enrichment of Cells with Cancer Stem Cell-Like Markers in Relapses of Chemoresistant Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma.

Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epidermal Growth Factor Inhibition.

The metabolic co-regulator PGC1α suppresses prostate cancer metastasis.

Protein Profiling of Bladder Urothelial Cell Carcinoma.

Ornithine Decarboxylase Is Sufficient for Prostate Tumorigenesis via Androgen Receptor Signaling.

The role of GATA2 in lethal prostate cancer aggressiveness.

Reappraising hyalinizing clear cell carcinoma: A population-based study with molecular confirmation.

Implementation of a Precision Pathology Program Focused on Oncology-Based Prognostic and Predictive Outcomes.

The nuclear transport receptor Importin-11 is a tumor suppressor that maintains PTEN protein.

miR-424(322)/503 is a breast cancer tumor suppressor whose loss promotes resistance to chemotherapy.

Targeting sarcoma tumor-initiating cells through differentiation therapy.

PTEN counteracts FBXL2 to promote IP3R3- and Ca(2+)-mediated apoptosis limiting tumour growth.

mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer.

Erratum: The metabolic co-regulator PGC1α suppresses prostate cancer metastasis.

Myocardial Amyloid Quantification with Look-Locker Magnetic Resonance Sequence in Cardiac Amyloidosis. Diagnostic Accuracy in Clinical Practice and Histological Validation.